Mycophenolate mofetil and methotrexate efficacy in dermatomyositis

Br J Dermatol. 2022 Sep;187(3):437-438. doi: 10.1111/bjd.21235. Epub 2022 May 27.

Authors

Madison Grinnell^{1

2}, Emily Keyes^{1

2}, DeAnna Diaz^{1

2}, Thomas Vazquez^{1

2}, Rui Feng³, Victoria P Werth^{1

2}

Affiliations

¹ Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Corporal Michael J. Crescenz Veterans Administration Medical Center, Philadelphia, PA, USA.
³ Department of Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

No abstract available

Publication types

Letter

MeSH terms

Dermatomyositis* / drug therapy
Humans
Immunosuppressive Agents / therapeutic use
Methotrexate / therapeutic use
Mycophenolic Acid* / therapeutic use

Substances

Immunosuppressive Agents
Mycophenolic Acid
Methotrexate

Grants and funding

R01 AR076766/AR/NIAMS NIH HHS/United States